The prognosis of patients with breast cancer, especially triple-negative breast cancer and HER2-positive breast cancer, is still unsatisfactory, in spite of huge advancements in the aspect of its diagnosis and therapy have been achieved during the past decades (de la Mare et al., 2014). This evidence concerns the gene ERBB2 and breast carcinoma.